Human Genome Sciences’ Hepatitis C Drug Could Potentially Be Significant Revenue Earner
Zacks.com submits:
Recently, Human Genome Sciences Inc. (HGSI) announced interim results on hepatitis C candidate Zalbin from a mid-stage study. The study evaluated the safety and efficacy of Zalbin. The results revealed that a monthly dose of Zalbin was as effective as a weekly dose of Roche’s (RHHBY.PK) Pegasys (peginterferon alfa-2a), which is the current standard of care.
The study combined Zalbin with ribavirin in 391 treatment-naive patients infected with genotypes 2 and 3 hepatitis C. Full results from the study are expected to be presented later in the year.
Investing, Long Term Investment, stock market | admin March 25, 2010
RSS feed for comments on this post.
